Feasibility of focused ultrasound therapy for recurrent cervicitis with high-risk human papillomavirus infection.
OBJECTIVE
To investigate the feasibility of focused ultrasound therapy for recurrent cervicitis with high-risk human papillomavirus (HR-HPV) infection.


METHODS
This was a prospective clinical study, in which 20 patients with HR-HPV-positive recurrent cervicitis were enrolled. Focused ultrasound therapy was performed by one gynecologist. All patients were followed up for 6 months after ultrasound therapy. Telephone interviews, colposcopic examinations and Hybrid Capture II tests were performed to assess the safety and effectiveness of focused ultrasound therapy for HR-HPV-positive cervicitis.


RESULTS
Ultrasound therapy was tolerated well, and no severe complications were observed in any patient. Vaginal discharge was found intermittently in 95% of patients. Without any intervention this disappeared 1 month after ultrasound therapy. Patients' symptoms were relieved significantly by ultrasound therapy, including 88.9% patients who had abundant leukorrhea, 80% who had pelvic pain and 87.5% who had postcoital bleeding. No colposcopic evidence of cervicitis remained postoperatively in 75% of patients, and cytological examination showed that the lesions had disappeared in 80% of patients. Follow-up HPV testing revealed that 75% of patients presented negative HR-HPV infection following treatment.


CONCLUSIONS
Focused ultrasound therapy is feasible and effective in the treatment of patients with HR-HPV-positive cervicitis. It may provide a useful non-invasive treatment for recurrent cervicitis with HR-HPV infection.
Institute of Ultrasonic Engineering in Medicine, Chongqing Medical University, Chongqing, China. licz@haifu.com.cn
C-Z
CZ
Li
Z-B
ZB
Wang
X
X
Yang
Y
Y
Tang
D
D
Wang
Y
Y
Huang
X-F
XF
Fan
D000328:Adult; D005240:Feasibility Studies; D005260:Female; D057086:High-Intensity Focused Ultrasound Ablation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D030361:Papillomavirus Infections / Q000000981:diagnostic imaging / Q000628:therapy*; D011230:Precancerous Conditions / Q000000981:diagnostic imaging / Q000628:therapy*; D011446:Prospective Studies; D055502:Secondary Prevention; D016896:Treatment Outcome; D018084:Ultrasonography, Interventional; D002575:Uterine Cervicitis / Q000000981:diagnostic imaging / Q000628:therapy*; D019522:Vaginal Discharge